产品
编 号：F762087
分子式：C20H20N6O5S
分子量：456.48
分子式：C20H20N6O5S
分子量：456.48
产品类型
规格
价格
是否有货
结构图
CAS No: 2816165-02-1
产品详情
生物活性：
SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases.
体外研究：
SARS-CoV-2 nsp14-IN-1 (Compound 3) displays an excellent selectivity profile for Nsp14 MTase With an IC50 value of 0.061 μM.SARS-CoV-2 nsp14-IN-1 (Compound 3) shows low passive diffusion rates in PAMPA.SARS-CoV-2 nsp14-IN-1 (Compound 3) does not suffer major metabolic liabilities in human plasma and liver S9 fractions.
SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases.
体外研究：
SARS-CoV-2 nsp14-IN-1 (Compound 3) displays an excellent selectivity profile for Nsp14 MTase With an IC50 value of 0.061 μM.SARS-CoV-2 nsp14-IN-1 (Compound 3) shows low passive diffusion rates in PAMPA.SARS-CoV-2 nsp14-IN-1 (Compound 3) does not suffer major metabolic liabilities in human plasma and liver S9 fractions.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备